Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A

Autor: Pratima Chowdary, Manuel Carcao, Pål A. Holme, Victor Jiménez‐Yuste, Steven R. Lentz, Judi Møss, Lone H. Poulsen, Chunduo Shen, Alberto Tosetto, Allison Wheeler, Elena Santagostino

Publikováno v: Research and Practice in Thrombosis and Haemostasis, Vol 3, Iss 3, Pp 542-554 (2019)

Abstract Background N8‐GP is an extended half‐life recombinant factor VIII developed for prophylaxis and treatment of bleeds in patients with hemophilia A. Objective To assess pharmacokinetic (PK) characteristics of N8‐GP in previously treated

Externí odkaz: https://doaj.org/article/9e72b2ac203c43c88c631ec0301b622f

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials

Autor: Kingsley Hampton, Steven R. Lentz, Chunduo Shen, Elena Santagostino, Karina Meijer, Anne T. Neff, Jameela Sathar, Alberto Tosetto, Andrea Landorph, László Nemes, Pratima Chowdary

Publikováno v: Haemophilia, 26(3), 450-458. Wiley
Haemophilia

Introduction Turoctocog alfa pegol is a glycoPEGylated recombinant factor VIII (FVIII) with an extended half‐life developed for prophylaxis, treatment of bleeds and perioperative management in patients with haemophilia A. Aim Evaluate the efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b7bc6b122013aec6ebabd988a3718a5
https://doi.org/10.1111/hae.13980

Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5

Autor: Andrea Landorph, Sonata Saulytė Trakymienė, Marina Economou, Chunduo Shen, Susan Kearney, Gili Kenet

Publikováno v: Journal of thrombosis and haemostasis: Special Issue: N8-GP (turoctocog alfa pegol; Esperoct®): A state-of-the-art extended half-life recombinant factor VIII molecule for patients with hemophilia A, Hoboken : Wiley, 2020, vol. 18, suppl. 1, p. 15-25
Journal of Thrombosis and Haemostasis

Background N8‐GP (turoctocog alfa pegol; Esperoct®, Novo Nordisk A/S, Bagsvaerd, Denmark) is a glycoPEGylated, extended half‐life human recombinant factor VIII (FVIII). Objective Here, we report end‐of‐trial safety and efficacy results from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3d3c89b6aa34f0e7e836a0aa1424972
https://repository.vu.lt/VU:ELABAPDB93078730&prefLang=en_US

Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs

Autor: Mohammad I. Hasan, Zafar Ahmed Latif, Jian-Wen Chen, Guillermo González Gálvez, Philip Home, Chunduo Shen

Publikováno v: Diabetes care. 37(5)

OBJECTIVE Individualization of therapy choices requires the prediction of likely response. Predictor and explanatory factors of change in HbA1c were studied using data from a large observational study of starting insulin analog therapy (the A1chieve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad36b798ff3a39fb98501e746d2ab9d3
https://pubmed.ncbi.nlm.nih.gov/25061152

P316 Estimation de la réduction du risque cardiovasculaire dans un sous-groupe de patients de l’étude A1chieve en utilisant l’algorithme UKPDS

Autor: León Litwak, Alexey Zilov, G. González Gálvez, A. Shinde, Pradana Soewondo, A. Al Gunaid, S. Shah, J. Courrèges, Chunduo Shen

Publikováno v: Diabetes & Metabolism. 40:A102

Objectif Estimer le risque de developper un evenement cardiovasculaire (CV) dans un sous-groupe de patients de l'etude A1chieve sans maladie/complication CV. Patients et methodes A1chieve est une etude internationale, multicentrique, prospective, non

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::60708dcb0f5670ef69c3a0673f59983e
https://doi.org/10.1016/s1262-3636(14)72607-2